TSLA
Tesla
-- 419.410 NVDA
NVIDIA
-- 138.039 PLTR
Palantir
-- 72.770 ADBE
Adobe
-- 473.770 AMD
Advanced Micro Devices
-- 131.098 
NEWS
BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®
Wednesday, 11th December at 7:50 am
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the literature
Wednesday, 11th December at 7:50 am
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6 months for those treated since 2022), double that of comparable patients in the literature
Final Phase 2 OS calculation is pending as many patients remain alive well over 1 year after starting the study
Median OS of 13.7 months in breast cancer patients with central nervous system (CNS) metastasis treated with the Bria-IMT™ regimen alone or in combination with an immune check point inhibitor (CPI)
Five BriaCell posters (four today and one on Dec 13th) showcase robust survival and clinical benefit data, plus key biomarker data from Phase 2 trial of Bria-IMT™ in metastatic breast cancer (MBC)
Biomarkers identify patients who benefit from treatments with the Bria-IMT™ regimen
No toxicity related discontinuations
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment